Until recently, guideline directed medical therapy for HFpEF and HFmrEF was aimed at symptom control with mostly diuretic-based treatments. The publication of EMPEROR-PRESERVED in 2021 prompted changes in the AHA/ACC/HFSA guidelines, assigning a 2a recommendation across the SGLT-2 inhibitor class for use in this patient population. Since then, the heart failure community has been waiting in anticipation for the results of DELIVER – the largest SGLT-2 inhibitor trial in this population to date and viewed by many, as an important validation of this class of medication in HFpEF/HFmrEF.
In this first episode of our new podcast series, Heart Failure in Focus, Dr Muthiah Vaduganathan is joined by Prof Scott Solomon to discuss the DELIVER data which was released at the ESC Congress 2022 in Barcelona. During this fascinating interview, you will get insight into the uniqueness of the DELIVER trial design, the importance of its design for key patient groups and what the results mean for clinical practice.
Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO.
This podcast is supported by an unrestricted educational grant from AstraZeneca.